JPWO2019199972A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019199972A5 JPWO2019199972A5 JP2020555883A JP2020555883A JPWO2019199972A5 JP WO2019199972 A5 JPWO2019199972 A5 JP WO2019199972A5 JP 2020555883 A JP2020555883 A JP 2020555883A JP 2020555883 A JP2020555883 A JP 2020555883A JP WO2019199972 A5 JPWO2019199972 A5 JP WO2019199972A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655431P | 2018-04-10 | 2018-04-10 | |
| US62/655,431 | 2018-04-10 | ||
| PCT/US2019/026788 WO2019199972A1 (en) | 2018-04-10 | 2019-04-10 | Compounds for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521200A JP2021521200A (ja) | 2021-08-26 |
| JPWO2019199972A5 true JPWO2019199972A5 (ru) | 2022-04-19 |
Family
ID=68164559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555883A Pending JP2021521200A (ja) | 2018-04-10 | 2019-04-10 | 癌の処置のための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11530207B2 (ru) |
| EP (1) | EP3781564B1 (ru) |
| JP (1) | JP2021521200A (ru) |
| KR (1) | KR20200142039A (ru) |
| CN (1) | CN112272666A (ru) |
| WO (1) | WO2019199972A1 (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| WO2020163375A1 (en) * | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2020163541A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163401A1 (en) * | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP2022523148A (ja) * | 2019-02-05 | 2022-04-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163647A1 (en) * | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021071981A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| WO2021071983A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| WO2021071984A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
| KR20220158236A (ko) | 2020-02-28 | 2022-11-30 | 레믹스 테라퓨틱스 인크. | 핵산 스플라이싱을 조절하기 위한 피리다진 유도체 |
| US20230142338A1 (en) | 2020-02-28 | 2023-05-11 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| EP4110785A1 (en) | 2020-02-28 | 2023-01-04 | Remix Therapeutics Inc. | Fused bicyclic compounds useful for modulating nucleic acid splicing |
| IL295955A (en) | 2020-02-28 | 2022-10-01 | Remix Therapeutics Inc | Compounds and Methods for Splicing Regulation |
| US20230167093A1 (en) | 2020-04-08 | 2023-06-01 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3175193A1 (en) | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| JP2023532331A (ja) | 2020-07-02 | 2023-07-27 | リミックス セラピューティクス インコーポレイテッド | 核酸をスプライシングするため及び増殖性疾患を処置するための修飾因子としての５－［５－（ピペリジン－４－イル）チエノ［３，２－ｃ］ピラゾール－２－イル］インダゾール誘導体及び関連する化合物並びにスプライシングを調節するための化合物及び方法 |
| BR112022027107A2 (pt) | 2020-07-02 | 2023-03-14 | Remix Therapeutics Inc | Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina e compostos relacionados como moduladores para splicing de ácidos nucleicos e para o tratamento de doenças proliferativas |
| TW202216697A (zh) * | 2020-08-05 | 2022-05-01 | 美商史凱霍克醫療公司 | 用於調節剪接之組成物 |
| WO2022060951A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| CN112662780A (zh) * | 2021-01-29 | 2021-04-16 | 复旦大学附属中山医院 | 检测hnrnpm表达的试剂在制备诊断和/或预后判断肝癌中的应用及药物组合物 |
| WO2023034827A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| IL311135A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Splicing Modulation Compounds and Methods |
| AU2022339925A1 (en) | 2021-08-30 | 2024-03-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034833A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202330552A (zh) | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| WO2023064880A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| WO2023133225A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202337442A (zh) | 2022-01-05 | 2023-10-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US7189737B2 (en) | 1991-08-09 | 2007-03-13 | Research Triangle Institute | Cocaine receptor binding ligands |
| US5128118A (en) * | 1990-08-09 | 1992-07-07 | Research Triangle Institute | Cocaine receptor binding ligands |
| GB0311201D0 (en) * | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| JP2008517032A (ja) | 2004-10-20 | 2008-05-22 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環式アリール誘導体及びその医薬用途 |
| US7834178B2 (en) * | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| FR2926297B1 (fr) * | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| ES2663398T3 (es) | 2008-03-27 | 2018-04-12 | Grünenthal GmbH | Derivados de 4-aminociclohexano sustituidos |
| MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
| RU2016109324A (ru) | 2013-08-19 | 2017-09-26 | Ф. Хоффманн-Ля Рош Аг | Способ скрининга |
| EP3053577A1 (en) * | 2015-02-09 | 2016-08-10 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| JP6884102B2 (ja) * | 2015-02-09 | 2021-06-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための化合物 |
| WO2016196386A1 (en) * | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| ES2879995T3 (es) * | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
-
2019
- 2019-04-10 US US17/046,245 patent/US11530207B2/en active Active
- 2019-04-10 JP JP2020555883A patent/JP2021521200A/ja active Pending
- 2019-04-10 WO PCT/US2019/026788 patent/WO2019199972A1/en unknown
- 2019-04-10 KR KR1020207032337A patent/KR20200142039A/ko unknown
- 2019-04-10 EP EP19785483.9A patent/EP3781564B1/en active Active
- 2019-04-10 CN CN201980037767.2A patent/CN112272666A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019199972A5 (ru) | ||
| JP2020537657A5 (ru) | ||
| JP2020528889A5 (ru) | ||
| TW200403210A (en) | Benzamide derivatives | |
| WO2009009501A4 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| WO2019129216A1 (zh) | 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用 | |
| JP2021534259A (ja) | ＪＡＫ阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン化合物およびその使用 | |
| CN105263924A (zh) | Cxcr7受体调节剂 | |
| WO2019137201A1 (zh) | 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 | |
| WO2021104488A1 (zh) | 作为jak抑制剂的三并杂环类化合物及其应用 | |
| CN112513006A (zh) | 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺 | |
| WO2020156189A1 (zh) | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 | |
| WO2016041472A1 (zh) | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 | |
| JP2012501308A (ja) | ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 | |
| JP7381136B2 (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| JP2000516257A (ja) | タキキニンアンタゴニスト | |
| CN115066425A (zh) | Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用 | |
| KR102651280B1 (ko) | 치환된 피리다진온류 화합물과 그 용도 | |
| WO2023016527A1 (zh) | 一类苯并噁嗪螺环类化合物及其制备方法 | |
| JP2024505912A (ja) | 連環を含むｔｙｋ２阻害剤化合物 | |
| JP2015504070A (ja) | 炭素環ヌクレオシドならびにその医薬的使用および組成物 | |
| WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
| US20100331323A1 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives | |
| WO2022166991A1 (zh) | 吲哚啉类化合物 | |
| JPH10500987A (ja) | 療用複素環化合物 |